Clinical and experimental nephrology
-
Clin. Exp. Nephrol. · Aug 2018
Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
Recently, globotriaosylsphingosine (lyso-Gb3) has attracted interest as a biomarker of Fabry disease. However, little is known regarding its utility for the evaluation of the therapeutic efficacy. ⋯ Regular observation of plasma lyso-Gb3 and antibodies is useful for monitoring of Fabry patients during ERT.